CJC-1295 DAC Genopharm 5 mg

Catalogue entry: CJC-1295 DAC Genopharm 5 mg. Labelled content: 5 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

CJC-1295 DAC is a synthetic growth-hormone-releasing hormone analogue with a reactive group designed for albumin binding. That construction is a material part of its identity. It distinguishes the long-acting research compound from products described loosely as CJC-1295 or modified GRF without confirmation of the DAC group.

What the research measured

Jetté and colleagues examined albumin-linked GHRH analogues in 2005. Teichman and colleagues subsequently reported small placebo-controlled studies in healthy adults in the Journal of Clinical Endocrinology and Metabolism in 2006. Those experiments measured hormone responses and pharmacokinetics rather than muscle strength, sporting recovery or longevity.

Sporting claims and limitations

The relationship to Sermorelin is mechanistic: both concern the GHRH pathway, but their molecular designs differ. Ipamorelin instead stimulates a ghrelin-receptor pathway. Biological interaction between pathways does not establish the clinical value or safety of a retail combination. Endocrine stimulation raises questions about glucose regulation, fluid balance and effects in hormone-sensitive conditions that a favourable biomarker result cannot settle.

Product identity and documentation

For this item, ask whether the documentation specifically identifies the DAC construction, peptide sequence and relevant chemical form. A generic CJC certificate may refer to another active moiety. Match the report, analytical method and lot number to the supplied material. The declared milligram content is a label quantity, not evidence that this product reproduces a trial formulation.